<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/219841-novel-semisynthetic-macrolide-antibiotics-of-the-azalide-series by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 11:24:26 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 219841:NOVEL SEMISYNTHETIC MACROLIDE ANTIBIOTICS OF THE AZALIDE SERIES</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">NOVEL SEMISYNTHETIC MACROLIDE ANTIBIOTICS OF THE AZALIDE SERIES</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>novel semisynthetic macrolide antibiotics the azalide series The invention relates to substituted 9a-N-[N’-(benzenesulfonyl)carbamoyl-&amp;gammad;-aminopropyl] and 9a-N-[N’-(&amp;bgr;-cyanoethyl)-N’-(benzenesulfonyl)carbamoyl-&amp;gammad;-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series, of the formula (I) wherein R represents H or cladinosyl moiety, R&lt;1&gt; represents H or &amp;bgr;-cyanoethyl group an R&lt;2&gt; represents H or fluoro, chloro and methyl group, and pharmaceutically acceptable salts thereof with inorganic or organic acids, to the process for the preparation of pharmaceutical compositions as well as to the use their compositions for sterilization rooms and medical instruments as well as for protection of wall and wooden coatings. ABSTRACT The invention relates to substituted 9a-N-[N&#x27;-(benzenesulfonyl)carbamoyl- gamma-aminopropyl] and 9a-N-[N&#x27;-(beta-cyanoethyl)-N&#x27;- (benzenesulfonyl)carbamoyl-gamma-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5 0-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series, of the formula (I) wherein R represents H or ladinos moiety, R&lt;1&gt; represents H or beta-cyanoethyl group an R&lt;2&gt; represents H or fluoro, chloro and methyl group, and pharmaceutically acceptable salts thereof with inorganic or organic acids, to the process for the preparation of pharmaceutical compositions as well as to the use their compositions for sterilization rooms and medical instruments as well as for protection of wall and wooden coatings.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td> <br><br>
The present invention relates to substituted 9a-N-[N'-(benzenesulfonyl)carbamoyl-Y-<br>
-aminopropyl]       and       9a-N-[N' -(P-cyanoethyl)-N' -(benzenesulfonyl)carbamoyI-Y-<br>
aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5 <br>
O-desosaniinyl-9-<br>
-deoxo-9-dihydro-9a-aza-9a-homoerithronolide   A,   novel   semisynthetic   macrolide<br>
antibiotics of the azalide series having antibacterial activity, general formula 1,<br><br>
wherein R represents H or cladinosyl moiety, R' represents H or P-cyanoethyl group and R’ represents H or fluoro, chloro and methyl group, to pharmaceutically acceptable addition salts thereof with inorganic or organic acids, to a process for the preparation of the pharmaceutical compositions as well as to the use of these compositions for the sterilization the rooms and the medicinal instruments, as well as for the prevention of walls and wooden materials.<br>
Erithromycin A is a macrolide antibiotic , whose structure is characterized by 14-membered macrolactone ring having carbonyl group in C-9 position. It was found by McGuire in 1952 [Antibiot. Chemother., 2 (1952) 281] and for over 40 years it has been considered as a reliable and effective antimicrobial agent in the treatment of diseases caused by Gram-positive and some Gram-negative microorganisms. However, in an acidic medium it is easily converted into anhydroerythromycin A, an inactive C-6/C-12 metabolite of a spiroketal stiucture [P. Kurath et al., Experientia 27 (1971) 362].It is well-known that spirocyclisation of aglycone ring of erythromycin A is successfully inhibited by a chemical transformation of C-9 ketones or hydroxy groups in C-6 and/or<br><br>
C-12 position. By the oximation of C-9 ketones [S. Dokid et al., Tetrahedron Lett. 1967:<br>
1945] and by subsequently modifying the obtained 9(E)-oxime into 9-<br>
-[0-(2-methoxyethoxy)methyloxime]erithromycin A (ROXITHROMYCIN) [G. S.<br>
Ambrieres, Fr. pat. 2,473,525,1981] or 9(S)-erithromycylamine [R. S. Egan et al., J. Org.<br>
Chem. 39 (1974) 2492] or a more complex oxazine derivative thereof, 9-deoxo-l 1-deoxy-<br>
9,ll-{iniino[2-(2-methoxyethoxyethylidene]oxy}-9(S)-erythromycin	A<br>
(DIRITHROMYCIN) [P. Lugar et al., J. Crist. Mol. Struct. 9 (1979) 329], novel semisynthetic macrolides were synthetized, whose basic characteristic, in addition to a greater stability in an acidic medium, is a better pharmacokinetics and a long half-time with regard to the parent antibiotic erythromycin A. In a third way for modifying C-9 ketones use is made of Beckmann rearrangement of 9(E)-oxime and of a reduction of the obtained imino ether (G. Kobrehel et al., U.S. Pat. 4,328,334, 1982.) into 11-aza-lO-deoxo-10-dihydroerythromycin A (9-deoxo-9a-aza-9a-homoerythromycin A) under broadening the 14-member ketolactone ring into a 15-member azalactone ring. By reductive N-methylation of 9a-amino group according to Eschweiler-Clark process (G. Kobrehel et al., BE Pat. 892,357,1982.) or by a preliminary protection of amino group by means of conversion into the coresponding N-oxides and then by alkylation and reduction [G. M. Bright, U.S. Pat., 4,474,768, 1984.] N-methyl-U-aza-lO-deoxo-lO-dihydroerythromycin A (9-deoxo-9a-methyI-9a-aza-9a-homoerithromycin A, AZITHROMYCIN) was syntetized, a prototype of azalide antibiotics, which, in addition to a broad antimicrobial spectrum including Gram-negative bacteria and intrcellular microorganisms, are characterized by a specific mechanism of transport to the application site, a long biological half-time and a short therapy period. In EP A 0316128 (Bright G. M. et al.) novel 9a-allyl and 9a-propargyl derivatives of 9--deoxo-9a-aza-9a-homoerythromycin A are disclosed and in U.S. Pat. 4,492,688, from 1985 (Bright G. M.) the synthesis and the antibactertial activity of the corresponding cyclic ethers are disclosed. In the there are further disclosed the syntesis and the activity spectrum of novel 9-deoxo-9a-aza-ll-deoxy-9a-homoerythromycin A 9a,ll-cyclic carbamates and O-methyl derivatives thereof (G. Kobrehel et al., J. Antibiot. 46 (1993) 1239-1245).<br><br>
By reaction of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A with isocyanates or isothiocyanates respectively [N. Kujundzic et al. Croat. Pat. 931480, 1993.], 9a-N-(N'-carbamoyl) and 9a-N-(N'-thiocarbamoyl) derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A with a certian antibacterial activity are obtained.<br>
According      to      the      known      and      established      Prior      Art,      9a-N-[N'-<br>
(benzenesul fon yl)c arbamoyl -y-<br>
-aminopropyl]        and       9a-N-[N'-(P'Cyanoethyl)-N'-(benzenesulfonyl)carbamoyl-'Y-<br>
aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-<br>
O-desosaminyl-9-<br>
-deoxo-9-dihydro-9a-aza-9a-homoerithronolide   A   and   pharmaceutically   acceptable<br>
additoin salts thereof with inorganic or organic acids, a process for the preparation<br>
thereof as well as the preparation methods and use an pharmaceutical preparations have<br>
not been disclosed as yet.<br>
It has been found and it is object of the present invention, that 9a-N-[N'-(benzene-<br>
sulfonyl)carbamoyl-Y-aminopropyl] and 9a-N-[N'-(|3-cyanoethyl)-N'-(benzenesulfonyI)-<br>
carbamoyl-y-aminopropyl]	derivatives	of        9-deoxo-9-dihydro-9a-aza-9a-<br>
homoerithromycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-<br>
homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series and<br>
pharmaceutically acceptable addition salts thereof with inorganic or organic acids may<br>
be prepared by reacting 9a-N-(Y-aminopropyl) or 9a-N-[N'-(P-cyanoethyl)-y-<br>
aminopropyl]	derivatives	of	9-deoxo-9-dihydro-9a-aza-9a-<br>
-homoerithromycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-<br>
homoerithronolide A with phenylsulfonylisocyanate and optionally by reacting the<br>
obtained 9a-N-[N'-(benzenesulfonyl)carbamoyl-y-aminopropyl] and 9a-N-[N'-(P-<br>
cyanoethyl)-y-aniinopropyl]-derivatives	of	9-deoxo-9-dihydro-9a-aza-9a-<br>
homoerithromycin	A	and	5-0-desosaminyl-9-<br>
-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A with inorganic and organic acids.<br>
Technical Solution<br><br>
It has been found that novel 9a-N-[N'-(benzenesulfonyl)carbamoyl-(N'-benzenesulfo-<br>
nyl)carbamoyl-Y-aminopropyl]	and	9a-N-[N'-(P-cyanoethyl)-N'-<br>
(benzenesulfonyl)carbamoyl- -y-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-<br>
9a-homo-	erithromycin	A	and	5-0-<br>
-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithrono]ide A of the general formula 1, wherein R represents H or cladinosyl group, R' represents H or P-cyanoethyl moiety and R’ represents H or fluoro, chloro and methyl group<br>
0<br>
H     II N—S<br>
\  //<br>
-R’<br>
O<br>
N	R'<br>
°=
 <br>
HO<br>
-HO-<br>
‘"\...'<br>
OH’<br>
n-V’OH ‘‘<br><br>
N<br><br>
1<br>
may be prepared by reacting 9a-N-(Y-aminopropyl) and 9a-N-[N'-(P-cyanoethyl)-y-<br>
-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-<br>
O-<br>
-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A general formula 2,<br><br>
N—R'<br><br>
wherein R represents H or cladinosyl group and R' represents H or P-cyanoethyl moiety, with the substituted phenylsulfonylisocyanates general formula 3,<br><br>
wherein R represents H or fluoro, chloro and methyl group, in toluene, xylene or some other aprotic solvent, at a temperature 0° to 110°C.<br>
Pharmaceutically acceptable acid addition salts, which also represents an object of the<br>
present invention are obtained by reacting 9a-N-[N'-(benzenesulfonyl)carbamoyl-Y-<br>
aminopropyl]	and	9a-N-[N'-(p-cyanoethyl)-N'-(benzenesulfonyl)carbamoyl-Y-<br>
aminopropyl]	derivatives	of	9-<br>
-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9a-<br>
-aza-9a-homoerithronolide A with an at least equimolar amount of the corresponding inorganic or organic acid such as hydrochloric acid, hydroiodic acid, sulfuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, propionic acid, benzoic acid, benzene sulfonic acid, methane sulfonic acid, lauryl sulfonic acid, stearic acid, palmitic acid,<br><br>
succinic acid, ethylsuccinic acid, lactobionic acid, oxalic acid, salicylic acid and similar acid, in a solvent inert to the reaction. Addition salts are isolated by evaporating the solvent or, alternatively, by filtration after a spontaneous precipitation or a precipitation by the addition of a non-polar cosolvent.<br>
9a-N-[N'-(Benzenesulfonyl)carbamoyl-Y-aminopropyl]  and 9a-N-[N'-(|3-cyanoethyl)-N'-(benze- nesulfonyl)carbamoyl-Y-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homo-     erithromycin     A     and     5-0-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A of the general fonnula 1 and pharmaceutically acceptable addition salts with inorganic or organic acids thereof possess an antibacterial activity in vitro. Minimal inhibitory concentration (MIC) is defined as the concentration which shows 90% growth inhibition, and was determinated by broth dilution methods National Committe  for  Clinical  Laboratory  Standards   (NCCLS,  M7-A2  protocols).   Final concentration of test substances were in range from 64 to 0.125 mg/1. MIC levels for all compound were determinated on panel of susceptible and resistant Gram positive bacterial strains {S. aureus, S. pneumoniae and S. pyogenes) and on Gram negative strains (E. coli, H. influenzae, E. faecalis, M. catarrhalis).<br>
Test substances from Examples 1 to 7 and 15 to 21 were active on susceptible strains of S. pyogenes (MIC 0.125 to 4.0 mg/1), and on susceptible strains on S. pneumoniae (MIC 0.125 to 8.0 mg/1). MIC values on susceptibile S. aureus strains were from 1 to 16 mg/1. Substances from Examples 1 to 7 and 15 to 21 showed strong antimicrobial activities on most tested Gram negative strains; M. catarrhalis MIC from 0.25 to 16 mg/i, E. coli from 8 to 16 mg/1, E. faecalis from 2 to 8 mg/1.<br>
The obtained results for substances from Example 1 to 7 and 15 to 21 expressed as MIC in mg/1 suggest a potentional use thereof as sterilization agents of e.g. rooms and medical instmments and as industrial microbial agents e. g. for the protection of wall and wooden coatings.<br>
Process for the preparation of 9a-N-[N'-(benzenesulfonylcarbamoyl)-7-aminopropyl] and<br>
9a-N-<br>
-[N'-(P-cyanoethyl)-N'-(benzenesulfonyl)carbamoyl-7-aminopropyl]    derivatives   of   9-<br>
deoxo-9-<br><br>
-dihydro-9a-aza-9a-homoerithromycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9a-aza-<br>
9a-<br>
-homoerithronolide A of this invention is illustrated by the following Examples which<br>
should in no way be construed as a limitation of the scope thereof.<br><br>
Example 1<br>
9-Deoxo-9-dihydro-9a-N-[N'-(p-toIuensulfonyl)carbamoyl-Y-aminopropyll-9a-aza-9a--homoerithromycin A<br>
A mixture of 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(Y-aminopropyl)-9a--homoerithromycin A and 0.26 g (1.3 mmol) of p-toluensulfonylisocyanate in 30 ml dry toluene was stirred for on 1.0 hour at the temperature 0-5 °C to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol = 7:3, pure 9-deoxo-9-dihydro-9a-N-[N'-(p-<br>
-toluensulfonyl)carbamoyl-Y-aminopropyl]-9a-aza-9a-homoerithromycin A was obtained. MS(ES’)m/z = 989.<br>
Example 2<br>
9-Deoxo-9-dihydro-9a-N-[N'-(4-chlorobenzenesulfonyI)carbanioyl-Y-aminopropyl]-9a-aza--9a-homoerithromycin A<br>
From 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(Y-aminopropyl)-9a-homoerithromycin A and 0.28 g (1.3 mmol) of 4-chlorobenzenesuIfonyIisocyanate in 20 ml dry toluene the crude product was obtained, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol =1:1, pure 9-deoxo-9-dihydro-9a-N-[N'-(4-chIoro- benzenesulfonyl)carbamoyl-Y-aminopropyl]-9a-aza-9a-homoerithromycin A was obtained. MS(ES*)m/z = 1009.<br>
Example 3<br>
9-Deoxo-9-dihydro-9a-N-[N'-(benzenesulfonyl)carbamoyl-Y-aminopropyl]-9a-aza-9a--homoerithromycin A<br>
From     1.01     g     (1.28     mmol)     9-deoxo-9-dihydro-9a-aza-9a-(Y-aminopropyl)-9a-homoerithromycin A and 0.23 g (1.91 mmol) of benzenesulfonylisocyanate in 20 ml dry<br><br>
toluene the crude product was obtained, wherefrom by cluomatography on sillica gel<br>
column using the solvent system methylene-chloride : methanol = 1:1, pure 9-deoxo-9-<br>
dihydro-9a-N-[N'-(benzenesulfonyl)-	carbamoyl-Y-aminopropyl]-9a-aza-9a-<br>
homoerithromycin A was obtained. MS(ES’)m/z = 975.<br>
Example 4<br>
9-Deoxo-9-dihydro-9a-N-[N'-(o-toluenesulfonyl)carbamoyI-Y-aminopropyl]-9a-aza-9a--homoerithromycin A<br>
From 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(7-aminopropyl)-9a-<br>
horaoerithromycin A and 0.26 g (1.3 mmol) of o-toluensulfonylisocyanate in 20 ml dry<br>
toluene the crude product was obtained, wherefrom by chromatography on sillica gel<br>
column using the solvent system methylene-chloride : methanol = 1:1, pure 9-deoxo-9-<br>
dihydro-9a-N-[N'-(o-toluensuIfonyl)-	carbamoyl-Y-aminopropyl]-9a-aza-9a-<br>
homoerithromycin A was obtained. MS(ES*)m/z = 989.<br>
Example 5<br>
9-Deoxo-9-dihydro-9a-N-[N'-(2-chlorobenzenesuIfonyl)carbamoyl-y-aminopropyI]-9a-aza--9a-homoerithromycin A<br>
From 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-N-(Y-aminopropyl)-9a-homoerithromycin A and 0.28 g (1.3 mmol) of 2-chlorobenzenesulfonylisocyanate in 20 ml dry toJuene the crude product was obtained, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol = 7:3, pure 9-deoxo-9-dihydro-9a-N-[N'-(2-<br><br>
-chlorobenzenesulfonyl)carbamoyl-7-aminopropyl]-9a-aza-9a-homoerithromycin   A   was<br>
obtained.<br>
MSCES'-Wz = 1009.<br>
Example 6<br>
9-Deoxo-9-dihydro-9a-N-[N'-(4-fluorobenzenesulfonyl)carbamoyI-Y-aminopropyI]-9a-aza--9a-homoerithromycin A<br>
From 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-N-(Y-aminopropyl)-9a-aza-9a-homoerithromycin A and 0.28 g (1.3 mmol) of 4-fluorobenzenesulfonylisocyanate in 20 ml dry toluene the crude product was obtained, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol = 7:3, pure 9-deoxo-9-dihydro-9a-N-[N'-(4-<br>
-fluorobenzenesulfonyl)carbamoyl-Y-aminopropyl]-9a-aza-9a-homoerithromycin   A   was obtained. MS(ES-')m/z = 993.<br>
Example 7<br>
5-0-Desozaminyl-9-deoxo-9-dihydro-9a-N-(Y-aminopropyl)-9a-aza-9a--homoerithronoUde A<br>
The suspension of 10. 0 g (12.6 mmol) 9-deoxo-9-dihydro-9a-N-(Y-aminopropyl)-9a-aza-9a- homoerithromycin A 120 ml of hydrochloric acid (10 %) was stirred for 24 hours at a room temperature, the pH was adjusted to 9.5 - 10 by adding 5 N sodium hydroxide solution and was extracted with methylene chloride (3 x 40 ml). The combined organic layers was washed with water (2 x 50 ml), dried over anhydrous sodium sulfate, evaporated to drieness under reduced pressure to give crude product wherefrom by chromatography on sillica gel column using the solvent system methylene chloride : methanol = 7:3, pure 5-0-desozaminyl-9--deoxo-9-dihydro-9a-N-(Y-aminopropyl)-9a-aza-9a-homoerithronolide A was obtained. MS(ES’)m/z = 653.<br><br>
Exemple 8<br>
5-0-DesozaminyI-9-deoxo-9-dihydro-9a-N-[N'-(p-toIuenesuIfonyI)carbamoyI-Y--aniinopropyl]-9a-aza-9a-homoerithronolide A<br>
From 1.0 g (1.26 mmol) 5-0-desozaminyl-9-deoxo-9-dihydro-9a-N-(Y-aminopropyl)-9a-<br>
aza-<br>
-9a-homoerithionolide A and 0.34 g (1.73 mmol) of p-toluenesulfonylisocyanate in 20<br>
ml dry toluene the crude product was obtained, wherefrom by chromatography on sillica<br>
gel column using the solvent system methylene-chloride ; methanol : 25% ammonia =<br>
90      :      20      :      1.5,      pure      5-0-desozaminyl-9-deoxo-9-dihydro-9a-N-[N'-(p-<br>
toluenesulfonyl)carbamoyl-Y-<br>
-aminopropyl]-9a-aza-9a-homoerithronolide A was obtained.<br>
MS(ES’)m/z = 831.<br>
Example 9<br>
5-0-Desozaminyl-9-deoxo-9-dihydro-9a-N-[N'-(4-chlorobenzenesulfonyl)carbamoyl-7--aminopropyl]-9a-aza-9a-homoerithronolide A<br>
From 1.0 g (1.57 mmol) 5-0-desozanainyl-9-deoxo-9-dihydro-9a-N-(y-aniinopropyl)-9a-aza-<br>
-9a-homoerithronolide A and 0.36 g (1.765 mmol) of 4-chlorobenzenesulfonylisocyanate in 20 mi dry toluene the crude product was obtained, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol: 25% ammonia = 90 : 20 : 1,5, pure 5-0-desozaminyl-9-deoxo-9-dihydro-9a-N-[N'-(4-chlorobenzenesulfonyl)- carbamoyl-Y-aminopropyl]-9a-aza-9a-homoerithronolide A was obtained. MS(ES’)m/z = 851.<br><br>
xample 10 5-0-DesozaminyI-9-deoxo-9-dihydro-9a-N-[N'-(4-fluorobenzenesulfonyI)carbamoyl-y--aminopropyl]-9a-aza-9a-homoerithronolide A<br>
From 1.0 g (1.57 mmol) 5-0-desozaminyl-9-deoxo-9-dihydro-9a-N-(Y-aminopropyl)-9a-aza-9a-homoerithronolide A and 0.35 g (1.73 mmol) of 4-fluorobenzenesulfonylisocyanate in 25 nal dry toluene the crude product was obtained, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : 25% ammonia = 90 : 20 : 1,5 pure 5-0-desozaminyl-9-deoxo-9-dihydro-9a-N-[N'-(4-fluorobenzenesulfonyl)carbamoyl- -Y-aminopropyl]-9a-aza-9a-homoerithronolide A was obtained. MS(ES’)m/z = 835.<br>
Example 11<br>
5-0-DesozaniinyI-9-deoxo-9-dihydro-9a-N-[N'-(benzenesulfonyl)carbanioyl-Y--aniinopropyl]-9a-aza-9a-homoerithronoIide A<br>
From 1.0 g (1.57 mmol) 5-0-desozaminyl-9-deoxo-9-dihydro-9a-N-(Y-aimnopropyl)-9a-<br>
aza-<br>
-9a-homoerithronolide A and 0.30 g (1.65 mmol) of benzenesulfonylisocyanate in 25 ml<br>
dry toluene the crude product was obtained, wherefrom by chromatography on sillica gel<br>
column using the solvent system methylene-chloride : methanol : 25% ammonia = 90 :<br>
20	:	1,5,	pure	5-0-desozaminyl-9-deoxo-9-dihydro-9a-N-[N'-<br>
(benzenesulfonyl)carbamoyl-Y-aminopropyl]-<br>
-9a-aza-9a-homoerithronolide A was obtained.<br>
MS(ESV/z = 817.<br>
Example 12<br>
5-0-Desozaminyl-9-deoxo-9-dihydro-9a-N-[N'-(o-toIuenesulfonyl)carbamoyl-Y--aminopropyl]-9a-aza-9a-homoerithronolide A<br><br>
From 1.0 g (1.57 mmol) 5-0-desozaminyl-9-deoxo-9-dihydro-9a-N-(Y-aminopropyl)-9a-<br>
aza-<br>
-9a-homoerithronolide A and 0.33 g (1.65 mmol) of o-toluenesulfonylisocyanate in 25<br>
ml dry toluene the crude product was obtained, wherefrom by chromatography on sillica<br>
gel column using the solvent system methylene-chloride : methanol : 25% ammonia =<br>
90      :     20      :      1.5,      pure      5-0-desozaminyl-9-deoxo-9-dihydro-9a-N-[N'-(p-<br>
toluenesulfonyl)carbamoyl-Y-araino-    propyl]-9a-aza-9a-homoerithronolide    A    was<br>
obtained.<br>
MS(ES'")m/z = 831.<br>
Example 13<br>
5-0-DesozaminiyI-9-deoxo-9-dihydro-9a-N-[N'-(2-chlorobenzenesuIfonyl)carbamoyl-Y--aminopropyl]-9a-aza-9a-homoerithronolide A<br>
From 1.0 g (1.57 nrniol) 5-0-desozaminyl-9-deoxo-9-dihydro-9a-N-(Y-aminopropyl)-9a-<br>
aza-<br>
-9a-homoeritlironolide A and 0.33 g (1.65 mmol) of 2-chlorobenzenesulfonylisocyanate<br>
in 25 ml dry xylene the crude product was obtained, wherefrom by chromatography on<br>
sillica gel column using the solvent system methylene-chloride : methanol : 25%<br>
ammonia = 90  :  20  :   1.5,  pure 5-0-desozaminyl-9-deoxo-9-dihydro-9a-N-[N'-(2-<br>
chlorobenzenesulfonyl)carba- moyl-Y-aminopropyl]-9a-aza-9a-homoerithronolide A was<br>
obtained.<br>
MS(ES’)m/z = 851.<br>
Example 14<br>
9-Deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyI)-Y-aminopropyl]-9a-aza-9a-homoerithromycin A<br><br>
The solution of 10.0 g (15.7 mmol) 9-deoxo-9-dihydro-9a-N-(Y-aniinopropyl)-9a-aza~ 9a-<br>
-homoerithromycin A and 1.0 ml (18.0 mmol) acrylonitrile in 200 ml methanola was heated at the boiling temperature for a 10 hours and evaporated to drieness and the crude product was obtained where from by chromatography on sillica gel column using the solvent system methylene chloride : methanol : 25 % ammonia = 90 : 9 : 1.5 pure 9-deoxo-9-dihydio-9a-N-<br>
-[N'-(p-cyanoethyl)-y-aminopropyl]-9a-aza-9a-homoerithromycin A was obtained. MS(ES’)m/z = 877.<br>
Example 15<br>
9-Deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyl)-N'-(p-toIuenesuIfonyI)carbamoyI-Y--aminopropyl]-9a-aza-9a-homoerithromycin A<br>
From 1.0 g (1.18 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-7-aminopropyl]-<br>
9a-aza-<br>
-9a-homoerithromycin A and 0.25 g (1.25 nmiol) of p-toluenesulfonylisocyanate in 25<br>
ml dry toluene the crude product was obtained, wherefrom by chromatography on sillica<br>
gel column using the solvent system methylene chloride : methanol : 25 % ammonia =<br>
90	:	9	:	1.5,	pure	9-<br>
-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-N'-(p-toluenesulfonyl)carbamoyl-Y-<br>
aminopropyl]-<br>
-9a-aza-9a-homoerithromycin A was obtained.<br>
MS(ES+)m/z = 1042.<br>
Example 16<br>
9-Deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyI)-N'-(o-toluenesulfonyl)carbamoyl-Y--aminopropyI]-9a-aza-9a-homoerithromycin A<br>
From 1.0 g (1.18 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-Y-aminopropyl]-<br>
9a-aza-<br>
-9a-homoerithromycin A and 0.25 g (1.25 mmol) of o-toluenesulfonylisocyanate in 25<br><br>
mJ dry toluene the crude product was obtained, wherefrom by chromatography on sillica<br>
gel column using the solvent system methylene chloride : methanol : 25 % ammonia =<br>
90	:	9	:	1.5,	pure	9-<br>
-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-N'-(o-toluenesulfonyl)carbamoyl-Y-<br>
aminopropyl]-<br>
-9a-aza-9a-homoerithromycin A was obtained.<br>
MS(ES’)m/z = 1042.<br>
Example 17 9-Deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyl)-N'-(4-<br>
chlorobenzenesulfonyl)carbamoyl-Y--aminopropyl]-9a-aza-9a-homoerithromycin A<br>
From 1.0 g (1.18 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyl)-Y-aminopropyl]-<br>
9a-aza-<br>
-9a-homoerithromycin A and 0.27 g (1.25 mmol) of 4-chlorobenzenesulfonylisocyanate<br>
in 25 ml dry toluene the crude product was obtained, wherefrom by chromatography on<br>
sillica gel column using the solvent system methylene chloride : methanol : 25 %<br>
ammonia = 90  :  9  :   1.5, pure 9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-N'-(4-<br>
chlorobenzenesulfonyl)carbamoyl-Y-<br>
-aminopropyl]-9a-aza-9a-homoerithromycin A was obtained.<br>
MS(ES+)m/z=1051.<br>
Example 18<br>
9-Deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyl)-N'-(2-chlorobenzenesulfonyl)carbamoyl-Y--aminopropyl]-9a-aza-9a-homoerithroinycin A<br>
From 1.0 g (1.18 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-Y-aminopropyl]-<br>
9a-aza-<br>
-9a-homoerithromycin A and 0.27 g (1.25 mmol) of 2-chlorobenzenesuIfonylisocyanate<br>
in 25 ml dry toluene the crude product was obtained, wherefrom by chromatography on<br><br>
sillica gel column using the solvent system methylene chloride : methanol : 25 % ammonia = 90  :   9  :   1.5, pure 9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-N'-(2-<br>
chlorobenzenesulfonyl)carbamoyl-Y--aminopropyl]-9a-aza-9a-homoerithromycin A was obtained. MS(ES’)m/z = 1051.<br>
Example 19<br>
9-Deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyI)-N'-(benzenesulfonyI)carbamoyl-Y--aminopropyI]-9a-aza-9a-homoerithromycin A<br>
From 1.0 g (1.18 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-Y-aminopropyl]-<br>
9a-aza-<br>
-9a-homoerithromycin A and 0.23 g (1.25 mmol) of benzenesulfonylisocyanate in 25 ml<br>
dry toluene the cmde product was obtained, wherefrom by chromatography on sillica gel<br>
column using the solvent system methylene chloride : methanol: 25 % ammonia = 90 :<br>
9	:	1.5,	pure	9-<br>
-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-N'-(benzenesulfonyl)carbamoyl-y-<br>
aminopropyl]-<br>
-9a-aza-9a-homoerithromycin A was obtained.<br>
MS(ES"')m/z=1028.<br>
Example 20<br>
9-Deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyl)-N'-(4-fluorobenzenesuIfonyI)carbamoyl-y--aminopropyI]-9a-aza-9a-homoerithromycin A<br>
From 1.0 g (1.18 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-7-aminopropyl]-<br>
9a-aza-<br>
-9a-homoerithromycin A and 0.25 g (1.25 mmol) of 4-fluorobenzenesulfonylisocyanate<br>
in 25 ml dry toluene the crude product was obtained, wherefrom by chromatography on<br>
sillica gel column using the solvent system methylene chloride : methanol : 25 %<br><br>
ammonia =  90  :   9  :   1.5, pure  9-deoxo-9-dihydio-9a-N-[N'-((3-cyanoethyl)-N'-(4-<br>
fluorobenzenesulfonyl)carbamoyl-Y-<br>
-aminopropyl]-9a-aza-9a-homoerithromycin A was obtained.<br>
MS(ES’)in/z=10I4.<br>
Example 21<br>
5-0-DesosaminyI-9-deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyl)-y-aminopropyl]-9a-aza-9a--homoerithronolide A<br>
The solution of 10.0 g (15.7 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-(Y-<br>
-aminopropyl)-9a-aza-9a-homoerithronolide A and 0.8 ml (15.7 mmol) acrylonitrile in<br>
200 ml methanole was heated at the boiling temperature for a 10 hours and evaporated<br>
to drieness and the crude product was obtained wherefrom by chromatography on sillica<br>
gel column using the solvent system methylen chloride : methanol: 25 % ammonia = 90<br>
:	9	:	1.5	pure	5-0-<br>
-desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-Y-aminopropyl]-9a-aza-9a--homoerithronolide A was obtained. MS(ES')m/z = 688.<br>
Example 22<br>
5-0-Desosanilnyl-9-deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyl)-N'-(p--toluenesulfonyl)carbamoyl-Y-aminopropyI]-9a-aza-9a-homoerithronoUde A<br>
From 1,0 g (1,46 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-<br>
Y-<br>
-aminopropyl]-9a-aza-9a-homoerithronolide   A   and   0,31   g   (1,55   mmol)   of   p-<br>
-toluenesulfonylisocyanate in 25 ml dry toluene the crude prockict was obtained,<br>
wherefrom by chromatography on sillica gel column using the solvent system methylene<br>
chloride : methanol : 25 % ammonia = 90 : 9 : 1.5, pure 5-0-desosanunyl-9-deoxo-9-<br>
dihydro-9a-N-[N'-<br><br>
-(P-cyanoethyl)-N'-(p-toluenesulfonyI)carbamoyl-y-aminopropyl]-9a-aza-9a-homoerithronoli- de A was obtained. MS(ES’)m/z = 883.<br>
Example 23<br>
5-0-Desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyl)-N'-(4--chlorobenzenesuIfonyI)carbamoyl-Y-aminopropyl]-9a-aza-9a-homoerithronoUde A<br>
From 1.0 g (1.46 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-<br>
Y-<br>
-aminopropyl]-9a-aza-9a-homoerithronolide   A   and   0.36   g   (1.65   mmol)   of   4-<br>
chlorobenzenesulfonylisocyanate in 25 ml dry toluene the crude product was obtained,<br>
wherefrom by chromatography on sillica gel column using the solvent system methylene<br>
chloride : methanol : 25 % ammonia = 90 : 9 : 1.5, pure 5-0-desosaminyl-9-deoxo-9-<br>
dihydro-<br>
-9a-N-[N'-(P-cyanoethyl)-N'-(4-chlorobenzenesulfonyl)carbamoyl-Y-aminopropyl]-9a-<br>
aza-9a-<br>
-homoerithronolide A was obtained.<br>
MS(ES’)m/z = 889.<br>
Example 24<br>
5-0-DesosaminyI-9-deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyl)-N'-(2-chlorobenzene-suIfonyI)carbamoyI-Y-aminopropyl]-9a-aza-9a-homoeritIironolide A<br>
From 1.0 g (1.46 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-Y-aminopropyl]-9a-aza-9a-homoeritlironolide A and 0.36 g (1.65 mmol) of 2-chlorobenzenesulfonylisocyanate in 25 ml dry toluene the crude product was obtained, wherefrom by chromatography on sillica gel column using the solvent system methylene chloride : methanol ; 25 % ammonia = 90 : 9 : 1.5, pure 5-0-desosaminyl-9-deoxo-9-dihydro--9a-N-[N'-(P-cyanoethyl)-N'-(2-chlorobenzenesulfonyl)carbamoyl-Y-aminopropyl]-9a-<br><br>
aza-9a-<br>
-homoerithronolide A was obtained.<br>
MS(ES’)m/z = 8S9.<br>
Example 25<br>
5-0-Desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyI)-N'-(o--toluenesulfonyl)carbamoyl-Y-aminopropyl]-9a-aza-9a-hoinoerithronoUde A<br>
From 1.0 g (1.46 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-<br>
y-<br>
-aminopropyl]-9a-aza-9a-homoerithronolide A and 0.31 g (1.55 mmol) of o--toluenesulfonylisocyanate in 25 ml dry toluene the crude product was obtained, wherefrom by chromatography on sillica gel column using the solvent system methylene chloride : methanol : 25 % ammonia = 90 : 9 : 1.5, pure 5-0-desosaminy]-9-deoxo-9-dihydro-9a-N-[N'-<br>
-(P-cyanoethyl)-N'-(o-toluenesulfonyl)carbamoyl-y-aminopropyl]-9a-aza-9a-homoerithronoli- de A was obtained. MS(ES&gt;T/Z = 884.<br>
Example 26<br>
5-0-Desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyl)-N'--(benzenesulfonyl)carbamoyl-y-aniinopropyI]-9a-aza-9a-homoerithronolide A<br>
From 1.0 g (1.46 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-(P-cyanoethyl)-<br>
Y-<br>
-aminopropyl]-9a-aza-9a-homoerithronolide A and 0.36 g (1.65 mmol) of benzenesulfonylisocyanate in 25 ml dry toluene the crude product was obtained, wherefrom by chromatography on sillica gel column using the solvent system methylene chloride : methanol : 25 % ammonia = 90 : 9 : 1.5, pure 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-<br>
-(P-cyanoethyl)-N'-(benzenesulfonyl)carbamoyl-y-aminopropyl]-9a-aza-9a-homoerithronolide A was obtained.<br><br>
MS(ES+)m/z = 870.<br>
Example 27<br>
5-0-Desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyl)-N'-(4-fluorobenzenesulfonyl)carbamoyl-Y-aminopropyI]-9a-aza-9a-homoerithronolide A<br>
From 1.0 g (1.46 mmol) 5-0-desosaniinyl-9-deoxo-9-dihydro-9a-N-[N'-(p-cyanoethyl)-<br>
Y-<br>
-aminopropyl]-9a-aza-9a-homoerithronolide   A   and   0.36   g   (1.65   mmol)   of   4-<br>
-fluorobenzenesulfonylisocyanate in 25 ml dry toluene the crude product was obtained, wherefrom by chromatography on silica gel column using the solvent system ethylene chloride : methanol : 25 % ammonia = 90 : 9 : 1.5, pure 5-0-desosaminyl-9-deoxo-9-dihydro-<br>
-9a-N-[N'-(P-cyanoethyl)-N'-(4-fluorobenzenesulfonyl)carbamoyl-'y-aminopropyl]-9a-aza-9a-homoerithronolide A was obtained. MS(ES’)m/z = 888.<br><br><br>
WE CLAIM:<br>
1.	Substituted  9a-N-[N'-(benzenesulfonylcarbamoyl)-Y aminopropyl]  and  9a-N-<br>
[N'-(P-<br>
-cyanoethyl)-N'-(benzenesulfonyI)-7-aminopropyl]   derivatives  of 9-deoxo-9-dihydro-<br>
-9a-aza-9a-homoerithromycin A  and 5-0-desosaminyl-9-deoxo-9-dihydro-9a-<br>
aza-9a-<br>
-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide<br>
series having antibacterial action of the general formula 1,<br><br>
wherein R represents H or cladinosyl moiety, R' represents H or p-cyanoethyl moiety  and   R’  represents   H or  fluoro,   chloro   and   methyl  group   and pharmaceutical!y acceptable addition salts there of with inorganic or organic acids selected from hydrochloric acid, hydroiodic acid, sulfuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, propionic acid, benzoic acid, benzene sulfonic acid, methane sulfonic acid, lauryl sulfonic acid, stearic acid, palmitic acid, succinic acid, ethylsuccinic acid, lactobionic acid, oxalic acid and salicylic acid.<br>
2.	The   substance according to claim 1,   wherein    R represents cladinosyl group and R' = R' represent H.<br>
3.	The   substance according to claim 1,   wherein   R represents cladinosyl group, R' represents H and R’ represents 4-chloro group.<br><br>
4-	The   substance according to claim 1,   wherein  R represents cladinosyl<br>
group, R' represents H and R' represents 2-chloro group.<br>
5.	The   substance according to claim 1,   wherein   R represents cladinosyl group, R' represents H and R" represents 4-fluoro group.<br>
6.	The   substance according to claim 1,   wherein R represents cladinosyl group, R' represents H and R’ represents 4-methyl group.<br>
7.	The   substance according to claim 1,   wherein  R represents cladinosyl group, R' represents H and R’ represents 2-methyI group.<br>
8.	The   substance according to claim 1,   wherein R = R* = R" represent H.<br>
9.	The   substance according to claim 1,   wherein  R = R'represent H and R’ represents 4-chloro group.<br>
10.	The   substance according to claim 1,   wherein  R = R'represent H and R’ represents 2-chloro group.<br>
11-    The   substance according to claim 1,   wherein R = R represent H, and R" represents 4-fluoro group.<br>
12.	The   substance according to claim 1,   wherein   R = R' represent H, and R’ represents 4-methyl group.<br>
13.	The   substance according to claim 1,   wherein R = R'represent H, and R’ represent 2-methyI group.<br>
14.	The   substance according to claim 1,   wherein    R represents cladinosyl<br>
group, R' represents P-cyanoethyl group and R’ represents H.<br>
15.	The   substance according to claim 1,   wherein    R represents cladinosyl<br>
group, R' represents P-cyanoethyl group, and R’ represents 4-chloro group.<br>
16.	The   substance according to claim 1,   wherein R represents cladinosyl<br>
group, R' represents P-cyanoethyl group, and R’ represents 2-chloro group.<br>
17.	The   substance according to claim 1,   wherein     represents cladinosyl<br>
group, R' represents P-cyanoethyl group, and R’ represents 4-fluoro group.<br><br>
18.	The   substance according to claim 1,   wherein   R represents cladinosyl group, R' represents P-cyanoethyl group, andR’ represents 4-methyl group.<br>
19.	The   substance according to claim 1,   wherein   R represents cladinosyl group, R' represents P-cyanoethyl group, and R’ represents 2-methyl group.<br>
20.	The substance according to claim 1, wherein R = R’ represents H, and<br>
R' represents P-cyanoethyl group.<br>
21.	The substance according to claim 1, wherein R represents H, R'<br>
represents	P-<br>
-cyanoethyl group, and R’ represents 4-chloro group.<br>
22.	The   substance according to claim 1,   wherein   R represents H, R<br>
represents	p-<br>
-cyanoethyl group, and R" represents 2-chloro group.<br>
23.	The substance according to claim 1, wherein R represents H, R' represents	P--cyanoethyl group, and R’ represents 4-fluoro group.<br>
24.	The   substance according to claim 1,   wherein    ‘ represents H, R represents	P--cyanoethyl group, and R’ represents 4-methyI group.<br>
25.	The substance according to claim 1, wherein R represents H, R' represents	p--cyanoethyl group, and R’ represents 2-methyl group.<br>
26. A process for the preparation of 9a-N-[N'-(benzenesulfonyl)carbamoyI-Y-<br>
aminopropyl] and 9a-N-[N'-(P-cyanoethyl)-N'-(benzenesulfonyI)carbamoyl-y-<br>
aminopropyl] deriva- lives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A<br>
and	5-0-desosaminyl-9-<br>
-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A of the general formula 1,<br><br><br>
wherein R represents H or cladinosyl group, R* represents H or P-cyanoethyl<br>
group, and R’ represents H or fluoro, chloro and methyl group, characterized in<br>
that	9a-N-(Y-<br>
-aminopropyl) and 9a-N-[N'-(P-cyanoethyl)-Y-aniinopropyl] derivatives of 9-<br>
deoxo-<br>
-9-dihydro-9a-aza-9a-homoerithroniicyn   A   and   5-0-desosanunyl-9-deoxo-9-<br>
dihydro-<br>
-9a-aza-9a-homoeithronolide A general formula 2,<br><br><br>
wherein R represents H and cladinosyl group and R' represents H and p-cyanoethyl group is reacted with substituted phenylsulfonylisocyanate general formula 3<br><br>
wherein R’ represents H, chloro, fluoro and methyl group, in toluene, xylene or some other aprotic solvents, at a temperature 0°-110°C and then, if appropriate, to a reaction with inorganic or organic acids.<br>
27.	A  pharmaceutical composition comprising a pharmaceutically acceptable carier<br>
and an antibacterially effective amount of the subsatnces according to claim 1.<br>
28.	Compositions for sterilization rooms and medical instruments as well as for protection<br>
of wall and wooden coatings comprising the substance according to claims 1 to 25.<br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IGFic3RyYWN0LWR1cGxpY2F0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 abstract-duplicate.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IGFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IGNsYWltcy1kdXBsaWNhdGUucGRm" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 claims-duplicate.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IGNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IGNvcnJlc3BvbmRlbmNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IGNvcnJlc3BvbmRlbmNlLXBvLnBkZg==" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 correspondence-po.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IGRlc2NyaXB0aW9uKGNvbXBsZXRlKS1kdXBsaWNhdGUucGRm" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 description(complete)-duplicate.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IGRlc2NyaXB0aW9uKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 description(complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IGZvcm0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IGZvcm0tMTgucGRm" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IGZvcm0tMjYucGRm" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 form-26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IGZvcm0tMy5wZGY=" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IGZvcm0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IHBjdCBzZWFyY2ggcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 pct search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IHBjdC5wZGY=" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 pct.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE5Mi1jaGVucC0yMDA1IHBldGl0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">1192-chenp-2005 petition.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="219840-a-socket-for-a-coaxial-electrical-plugin-connector-and-an-electrical-connector-plug.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="219842-a-yarn-feeding-device.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>219841</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1192/CHENP/2005</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>27/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>04-Jul-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>13-May-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>10-Jun-2005</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>PLIVA - ISTRAZIVACKI INSTITUT D.O.O.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>Prilaz baruna Filipovica 29, HR-10000 Zagreb,</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>KUJUNDZIC, Nedjeljko</td>
											<td></td>
										</tr>
										<tr>
											<td>2</td>
											<td>BUKVIC KRAJACIC, Mirjana</td>
											<td></td>
										</tr>
										<tr>
											<td>3</td>
											<td>BRAJSA, Karmen,</td>
											<td></td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K31/71</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/HR2003/00057</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2003-11-10</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>P 20020886A</td>
									<td>2002-11-11</td>
								    <td>Croatia</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/219841-novel-semisynthetic-macrolide-antibiotics-of-the-azalide-series by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 11:24:27 GMT -->
</html>
